Evaluation of the delayed renal function after controlled donor cardiac death using hypothermic machine perfusion compared with cold storage: Looking for a precise diagnosis

By: Etcheverry Giadrosich B.R.¹, Riera Canals L.¹, Fiol Riera M.¹, Suarez Novo J.¹, Melilli Melilli E.², Bestard Matamoros O.², De Lama Salvado E.³, Romero Martinez N.³, Mora Salvador J.⁴, Bajen Lazaro M.⁴, Vigués Julia F.¹

¹Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ²Hospital Universitari de Bellvitge, Dept. of Nephrology, Barcelona, Spain, ³Hospital Universitari de Bellvitge, Dept. of Radiology, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, Dept. of Nuclear Medicine, Barcelona, Spain

Aims and objectives of this presentation 1225

Donation after controlled circulatory death, type III. Experience and results over 4 years in a single institution, HUGTIP

By: Castillo C.¹, Areal Calama J.¹, Perez Mir M.², Buisan Rueda O.¹, Gonzalez Satue C.¹

¹Hospital Universitari Germans Trias i Pujol, Dept. of Urology, Badalona, Spain, ²Hospital Universitari Germans Trias i Pujol, Dept. of Nefrology, Badalona, Spain

Aims and objectives of this presentation 1226

Maastricht III kidneys: Does donor age influence DGF or graft survival?

By: Fernandez-Concha Schwalb J.¹, Etcheverry B.¹, Riera L.¹, Fiol M.¹, Bonet X.¹, Suarez J.F.¹, Bestard O.², Vigués F.¹

¹Bellvitge University Hospital, Dept. of Urology, Barcelona, Spain, ²Bellvitge University Hospital, Dept. of Nephrology, Barcelona, Spain

Aims and objectives of this presentation 1227
1228  Kidneys received from living donors over 70 years of age: Are those feasible as the grafts?

Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan

Aims and objectives of this presentation

1229  Management of end-stage renal disease patients diagnosed with active surveillance-eligible prostate cancer during pre-transplantation work-up: A decision analysis

By: Bieri U.1, Hübel K.2, Seeger H.2, Kulkarni G.S.3, Sulser T.1, Hermanns T.1, Wettstein M.S.1

1University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, 2University Hospital Zurich, Dept. of Nephrology, Zurich, Switzerland, 3Princess Margaret Cancer Centre, University Health Network, Division of Urology, Dept. of Surgery, Toronto, Canada

Aims and objectives of this presentation

1230  Incidence, management and clinical outcomes of prostate cancer in kidney transplant recipients

Beaumont Hospital, Dept. of Urology and Transplant Surgery, Dublin, Ireland

Aims and objectives of this presentation

1231  Body fat area as a predictive marker of new-onset diabetes mellitus after kidney transplantation

By: Taoka R., Abe Y., Naito H., Miyauchi Y., Matsuoka Y., Tajima M., Kato T., Tsunemori H., Ueda N., Sugimoto M., Kakehi Y.
Kagawa University, Dept. of Urology, Kagawa, Japan

Aims and objectives of this presentation

1232  The level of QOL improves slower in preemptive kidney transplantation than the one in non-preemptive kidney transplantation

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan
<table>
<thead>
<tr>
<th>1233</th>
<th>A novel, specific RIPK1 inhibitor reduces necroptosis and provides significant benefit in ischemic kidney injury in mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Gallagher K.M.¹, Beal A.², Finger J.², Hughes J.¹, Ross J.¹, Marson L.¹, Bertin J.², Ferenbach D.¹, Boulter L.³, Laird A.⁴, Leung S.⁴, Wigmore S.¹, Harrison E.⁵</td>
<td></td>
</tr>
<tr>
<td>¹University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom, ²GlaxoSmithKline, Pattern Recognition Receptor DPU, Collegeville, United States of America, ³University of Edinburgh, MRC Institute of genetics and molecular medicine, Edinburgh, United Kingdom, ⁴Western General Hospital Edinburgh, Dept. of Urology, Edinburgh, United Kingdom, ⁵University of Edinburgh, Centre for Medical Informatics, Usher Institute, Edinburgh, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1234</th>
<th>Tissue-resident memory CD8+ T cells in the kidney – implications for renal transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Friedersdorff F.¹, Dornieden T.¹, Sattler A.², Bergmann Y.², Ruhm A.², Schlomm T.¹, Kotsch K.²</td>
<td></td>
</tr>
<tr>
<td>¹Charité Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Dept. of Surgery, Berlin, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1235</th>
<th>Genetic predisposition with regards to the role of MMPs in allograft rejections following renal transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Srivastava A.¹, Prasad N.², Bhatt M.¹</td>
<td></td>
</tr>
<tr>
<td>¹SGPGIMS, Dept. of Urology and Renal Transplantation, Lucknow, India, ²SGPGIMS, Dept. of Nephrology, Lucknow, India</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1236</th>
<th>Early application of mTOR inhibitors reduce vascular inflammatory response after ischemia-reperfusion injury</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Wenzel M.¹, Haffer H.², Werner I.³, Richter M.⁴, Chun F.¹, Beiras-Fernandez A.⁵</td>
<td></td>
</tr>
<tr>
<td>¹University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²Charité Berlin, Dept. of Trauma Surgery, Berlin, Germany, ³University Hospital Frankfurt, Dept. of Cardiothoracic Surgery, Frankfurt, Germany, ⁴Kerkhoff Klinik, Dept. of Cardiothoracic Surgery, Bad Nauheim, Germany, ⁵University Hospital Mainz, Dept. of Cardiothoracic Surgery, Mainz, Germany</td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

1237

**Longitudinal serum N-glycan profiling predict biopsy-proven graft rejection after a living donor kidney transplantation**

By: Soma O.¹, Hatakeyama S.¹, Yoneyama T.¹, Noro D.¹, Tobisawa Y.¹, Hashimoto Y.¹, Koie T.², Sasaki H.³, Saito M.⁴, Harada H.⁵, Chikaraishi T.³, Ishida H.⁶, Tanabe K.⁶, Satoh S.⁴, Ohyama C.¹

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Gifu University School of Medicine, Dept. of Urology, Gifu, Japan, ³St. Marianna University of Medicine, Dept. of Urology, Kawasaki, Japan, ⁴Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁵Sapporo City General Hospital, Dept. of Kidney Transplant Surgery, Sapporo, Japan, ⁶Tokyo-Woman’s Medical University, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

1237

1238

**Thymoglobulin seems to increase hemorrhagic risk in sensitized kidney recipients**


Hospital del Mar, Dept. of Urology, Barcelona, Spain

Aims and objectives of this presentation

1238

17:04 - 17:11

**Summary**

J.D. Olsburgh, London (GB)